Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|July 21, 2023
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLCChristian Wilhelm Langberg, Henrik Horndalsveen, Åslaug Helland, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 13, 2022
[Checkpoint inhibitor-induced myocarditis]Geeta Gulati, Kristin Holm Tjessem, Henrik Horndalsveen, et al.
Frontiers in Immunology|December 17, 2024
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesotheliomaSaima Jamil Farooqi, Zhi Zhao, Åsa Kristina Öjlert, et al.
Frontiers in Oncology|August 16, 2024
Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trialHanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, et al.
Journal of Translational Medicine|June 1, 2021
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesotheliomaVilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study)Elin Marie Stensland, Simone Stensgaard, Inger Johanne Z Eide, et al.
Molecular Oncology|November 4, 2022
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trialHenrik Horndalsveen, Tine Norman Alver, Astrid Marie Dalsgaard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2026
ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumabHenrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, et al.
Acta Oncologica (Stockholm, Sweden)|March 19, 2026
How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?Frigg Å Sommervoll, Henrik Horndalsveen, Dag Einar Sommervoll, et al.
Frontiers in Oncology|November 7, 2025
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumabHenrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, et al.
Pageof 1